1150P Progression of advanced non-small cell lung cancer after durable clinical benefit on anti-PD-1/PD-L1 monotherapy: Prolonged post-progression survival and interest of tumor growth rate

Abstract

Immunotherapy blocking the PD-1/PD-L1 axis has been used as monotherapy for barely a decade in advanced non-small cell lung cancers (aNSCLC). Tumor progression can occur even after durable clinical benefit (DCB), defined as a minimum of 6 month of responsive/stable disease (per RECIST 1.1). It is qualified as oligo-progression (OPD) if occurring in ≤3 lesions. Clinical and radiological data in this situation is still scarce and heterogeneous, but needed to optimize care and understand the underlying biological processes.